- 专利标题： BRIDGED BICYCLIC INHIBITORS OF MENIN-MLL AND METHODS OF USE
-
申请号： US16082645申请日： 2017-03-15
-
公开(公告)号： US20190092783A1公开(公告)日： 2019-03-28
- 发明人: Tao Wu , Liansheng Li , Yi Wang , Pingda Ren , Jolanta Grembecka , Tomasz Cierpicki , Szymon Klossowski , Jonathan Pollock , Dmitry Borkin
- 申请人： Kura Oncology, Inc. , The Regents of The University of Michigan
- 申请人地址： US CA San Diego US MI Ann Arbor
- 专利权人： Kura Oncology, Inc.,The Regents of The University of Michigan
- 当前专利权人： Kura Oncology, Inc.,The Regents of The University of Michigan
- 当前专利权人地址： US CA San Diego US MI Ann Arbor
- 国际申请： PCT/US2017/022535 WO 20170315
- 主分类号： C07D495/04
- IPC分类号： C07D495/04 ; A61P35/02
摘要：
The present disclosure provides methods of inhibiting the interaction of menin with MLL1, MLL2 and MLL-fusion oncoproteins. The methods are useful for the treatment of leukemia, solid cancers, diabetes and other diseases dependent on activity of MLL1, MLL2, MLL fusion proteins, and/or menin. Compositions for use in these methods are also provided.
公开/授权文献
- US10752639B2 Bridged bicyclic inhibitors of menin-MLL and methods of use 公开/授权日：2020-08-25
信息查询
